MaxiVAX Company
MaxiVAX is a Swiss clinical-stage biotechnology company, currently performing a first-in-man (phase I) trial in various tumours with MVX-ONCO-1.
MaxiVAX’ mission is to develop alternative solutions to “established cancer therapies” that are more effective, are personalized and enable the patient to fight his own disease. MaxiVAX’ first treatment, MVX-ONCO-1 has been classified as an Advanced Therapeutic Product by the European Medicines Agency. The resulting approval procedure is different than that of a traditional drug and should generally allow a faster development until market approval with fewer and less extensive clinical trials.
Employee Number:
1-10
Headquarters:
Geneva, Geneve, Switzerland, Europe
Founded Date:
2005-01-01
Industry:
Cell, Gene & Biologics Therapeutics
Super Industry:
Biopharma & Life Science Tools
Phone Number:
+41 22 552 26 13
Investors:
EIC Accelerator
Ipo Status:
private
City:
Geneva
Region:
Geneve
Country:
Switzerland
Founders:
Bernard Mach, Nicolas Mach